The Food and Drug Administration (FDA) has released its staffing and operations plan in the event of a lapse in federal appropriations. While many FDA activities would continue under carryover user fee funding, others critical to food safety and seafood oversight could be delayed or paused.
What Continues
- FDA will continue activities tied to immediate threats to human health, including foodborne illness outbreak response, recalls, and emergency inspections.
- Import reviews will proceed to identify potential risks in seafood and other foods entering the U.S.
- Surveillance for adverse health events, regulatory testing tied to imminent threats, and enforcement actions will remain active.
- Staff funded by carryover user fees will continue oversight of certain programs, including tobacco regulation and medical product reviews.
What Pauses
- Longer-term food safety initiatives—including prevention-based policy development and nutrition programs—would be halted.
- Pre-market safety reviews of new animal food ingredients for livestock would stop, limiting FDA’s ability to confirm the safety of meat, milk, and eggs entering the food supply.
- Broader inspections and regulatory testing not tied to an imminent threat would be postponed.Research and innovation efforts to improve food safety systems would be severely reduced.
Staffing Impact
FDA expects to retain about 86% of staff during a funding lapse, with two-thirds exempt due to carryover funding and about one-fifth excepted because their roles directly protect human life or property. This includes staff supporting outbreak response, recalls, import inspections, and enforcement related to seafood safety.
Takeaway for the Seafood Industry
Day-to-day seafood imports and emergency food safety responses would continue, but prevention-focused programs and longer-term policy development could stall. Stakeholders should expect possible delays in inspections, guidance, and regulatory reviews unrelated to immediate health risks.